Beam Therapeutics (BEAM) Financials: History & Chart

Beam Therapeutics Inc.(BEAM)

Biotechnology · Cambridge, MA

$24.50+0.11 (+0.45%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About Beam Therapeutics Inc.

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Cambridge, MA

540 employees

www.beamtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Evans

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	156.03M	490K	31.74M	114.11M	9.70M	8.47M	7.47M	30.07M	14.27M
Cost of Goods Sold	126.49M	0.00	11.06M	5.67M	109.77M	101.76M	98.82M	101.44M	94.26M
Gross Profit	29.54M	490K	20.68M	108.44M	-100.07M	-93.29M	-91.35M	-71.38M	-79.99M
Gross Profit Margin	18.9%	100.0%	65.2%	95.0%	-1031.9%	-1102.0%	-1222.8%	-237.4%	-560.6%
Total Operating Expenses	407.57M	127.04M	127.90M	125.89M	26.74M	26.86M	27.94M	28.66M	26.52M
Research & Development	408.66M	95.10M	104.52M	99.28M	109.77M	101.76M	98.82M	101.44M	94.26M
Selling, General & Administrative	119.73M	31.95M	34.43M	26.61M	26.74M	26.86M	27.94M	28.66M	26.52M
Operating Income (EBIT)	-378.02M	-126.55M	-107.22M	-17.45M	-126.81M	-120.15M	-119.29M	-100.04M	-106.50M
Operating Margin	-242.3%	-25827.1%	-337.8%	-15.3%	-1307.6%	-1419.2%	-1596.9%	-332.7%	-746.4%
Income Before Tax (EBT)	-85.43M	-122.68M	-94.32M	244.30M	-112.73M	-102.29M	-109.27M	-90.35M	-96.67M
Interest Income	28.26M	7.49M	9.87M	N/A	10.90M	N/A	9.86M	10.93M	12.13M
Interest Expense	10.64M	N/A	N/A	10.64M	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	292.60M	3.88M	12.90M	261.74M	14.08M	17.86M	10.02M	9.68M	9.84M
Net Income	-85.43M	-122.68M	-94.32M	244.30M	-112.73M	-102.29M	-109.27M	-90.35M	-96.67M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-54.7%	-25036.3%	-297.2%	214.1%	-1162.4%	-1208.3%	-1462.8%	-300.5%	-677.5%
EBITDA	-355.78M	-121.14M	-101.61M	-11.78M	-121.25M	-114.61M	-113.76M	-94.59M	-101.03M
EBITDA Margin	-228.0%	-24723.1%	-320.2%	-10.3%	-1250.3%	-1353.8%	-1522.9%	-314.6%	-708.0%
Depreciation & Amortization	22.24M	5.41M	5.61M	5.67M	5.56M	5.54M	5.53M	5.44M	5.47M
EPS Basic	-0.82	-1.18	-0.91	2.37	-1.10	-1.00	-1.24	-1.09	-1.17
EPS Diluted	-0.86	-1.18	-0.91	2.33	-1.10	-1.00	-1.24	-1.09	-1.17
Weighted Average Basic Shares	104.33M	104.33M	103.26M	102.88M	102.57M	102.00M	87.97M	82.82M	82.41M
Weighted Average Diluted Shares	104.33M	104.33M	103.26M	104.93M	102.57M	102.00M	87.97M	82.82M	82.41M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	139.74M	63.52M	377.71M	60.92M	51.84M	24K	18K	0.00
Cost of Goods Sold	22.29M	367.56M	0.00	311.59M	232.13M	103.18M	54.62M	33.87M
Gross Profit	117.45M	-304.04M	377.71M	-250.67M	-180.29M	-103.16M	-54.60M	-33.87M
Gross Profit Margin	84.0%	-478.7%	100.0%	-411.5%	-347.8%	-429812.5%	-303338.9%	N/A
Total Operating Expenses	501.14M	111.53M	554.19M	87.81M	212.18M	29.60M	20.55M	11.87M
Research & Development	409.62M	367.56M	437.38M	311.59M	387.09M	103.18M	54.62M	33.87M
Selling, General & Administrative	113.82M	111.53M	116.81M	87.81M	57.22M	29.61M	20.55M	11.87M
Operating Income (EBIT)	-383.69M	-415.57M	-176.49M	-338.48M	-392.46M	-132.76M	-75.15M	-45.74M
Operating Margin	-274.6%	-654.3%	-46.7%	-555.6%	-757.0%	-553166.7%	-417522.2%	N/A
Income Before Tax (EBT)	-79.99M	-376.70M	-131.16M	-285.68M	-370.64M	-194.59M	-78.33M	-116.74M
Interest Income	N/A	49.09M	46.68M	15.30M	N/A	1.57M	2.49M	292K
Interest Expense	43.73M	N/A	N/A	N/A	N/A	N/A	187K	N/A
Other Income/Expense	303.70M	38.87M	45.32M	52.80M	21.83M	-61.83M	-3.17M	-71.00M
Net Income	-79.99M	-376.74M	-132.53M	-289.09M	-370.64M	-194.59M	-78.33M	-115.26M
Income Tax Expense	0.00	39K	1.37M	3.41M	0.00	0.00	0.00	0.00
Net Profit Margin	-57.2%	-593.1%	-35.1%	-474.5%	-714.9%	-810800.0%	-435144.4%	N/A
EBITDA	-377.36M	-393.64M	-146.95M	-324.33M	-385.01M	-128.03M	-71.65M	-45.09M
EBITDA Margin	-270.0%	-619.7%	-38.9%	-532.4%	-742.6%	-533437.5%	-398061.1%	N/A
Depreciation & Amortization	6.34M	21.93M	29.53M	14.15M	7.45M	4.73M	3.50M	650K
EPS Basic	-0.81	-4.58	-1.72	-4.13	-5.77	N/A	-1.53	-3.28
EPS Diluted	-0.81	-4.58	-1.72	-4.13	-5.77	N/A	-1.53	-3.28
Weighted Average Basic Shares	98.91M	82.31M	77.15M	70.02M	64.23M	46.73M	51.34M	35.14M
Weighted Average Diluted Shares	98.91M	82.31M	77.15M	70.02M	64.23M	46.73M	51.34M	35.14M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.